Article

OptiMedica partners with Topcon Medical Japan

OptiMedica Corp. will be expanding into Japan with the formation of an exclusive distribution agreement with Topcon Medical Japan Co., Ltd.

Santa Clara, CA-OptiMedica Corp. will be expanding into Japan with the formation of an exclusive distribution agreement with Topcon Medical Japan Co., Ltd.

According to the terms of the agreement, Topcon Medical Japan will be the sole local distributor of OptiMedica's pattern scan laser photocoagulator system (PASCAL), which is designed to treat a variety of retinal conditions including diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive disease.

"Topcon Medical Japan has a solid history of service to the ophthalmology community and has demonstrated a deep commitment to superior customer care," said Jean-Robert Strele, vice president of international business, OptiMedica. "These values are important to OptiMedica, and we look forward to entering this important partnership to serve the interests of Japanese ophthalmologists and patients."

"We strongly believe that adding the [photocoagulator] to our portfolio of outstanding products . . . will allow us to meet the needs of advanced medical care in the Japanese ophthalmic community,"said Hiroshi Fukuzawa, director, executive officer, and general manager of the Eye Care Business Unit of Topcon Medical Japan.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.